In this context, platelet horizontal miR-126-3p transfer and subsequent downregulation of PIK3/AKT2 signaling may be clinically relevant, especially for hypothesizing the future management of MV production and selective delivery to tumor cells. This evidence concerns the gene AKT2 and neoplasm.